Loading cancer entity…
Loading cancer entity…
Clinical trials
61 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (12)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03911388 | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04991870 | Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM | recruiting | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03657576 |
| Trial of C134 in Patients With Recurrent GBM(C134-HSV-1) |
| completed |
| Phase 1 |
| 19 |
| University of Alabama at BirminghamOTHER |
| 1 |
| Sep 3, 2026 |
| clinicaltrials |
| NCT07180927 | DLL3 CAR-T Therapy Targeting Brain Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03170141 | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | terminated | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07464925 | A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma | recruiting | Phase 1 | 30 | Tetragon Biosciences LtdINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05627323 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | terminated | Phase 1 | 1 | Chimeric TherapeuticsINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02649582 | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients(ADDIT-GLIO) | active not recruiting | Phase 1 / Phase 2 | 20 | University Hospital, AntwerpOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04222309 | Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) | suspended | Phase 1 | 10 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04968366 | Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery | completed | Phase 1 | 11 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06815432 | GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06193174 | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) | terminated | Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07179328 | Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy | recruiting | Phase 1 | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT03665545 | Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma(IMA950-106) | completed | Phase 1 / Phase 2 | 18 | University Hospital, GenevaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT01430351 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | terminated | Phase 1 | 144 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02078648 | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 74 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04842513 | Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma(GLIO-XS15) | completed | Phase 1 | 15 | University Hospital TuebingenOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06186440 | Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma(Glioblastoma) | unknown | Phase 1 / Phase 2 | 60 | Zhongnan HospitalOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT05363826 | Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac® | unknown | Phase 1 | 30 | Photolitec LLCINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT02311920 | Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | completed | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05095441 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | unknown | Phase 1 | 51 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04854044 | ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT02337426 | Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 12 | Virginia Commonwealth UniversityOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 15, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Sep 4, 2026source: clinicaltrials